siRNA and miRNA for the treatment of cancer

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Jankovic, Radmila ^a   Radulovic, S ^a   Brankovic Magic, M ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Cancer treatment; miRNA; RNA interference; siRNA

Indexed keywords

ARGONAUTE PROTEIN; BCR ABL PROTEIN; BEVASIRANIB; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR; MICRORNA; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOMATOMEDIN; VASCULOTROPIN;

CANCER GENE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOWN REGULATION; GENE CONTROL; GENE SILENCING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; RNA SYNTHESIS;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; GENE SILENCING; HUMANS; LEUKEMIA; MICRORNAS; NEOPLASMS; PROGNOSIS; PROTEIN BIOSYNTHESIS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING;

EID: 70350056427     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Fire A, Xu S, Montgomery MK et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811. (Pubitemid 28099681)
2. Meister G, Tuschl T. Mechanisms of gene silencing by double -stranded RNA. Nature 2004; 431: 343-349. (Pubitemid 39265674)
3. Proud CG. PKR: a new name and new roles. Trends Biochem Sci 1995; 20: 241-246.
4. Martinez J, Tuschl T. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev 2004; 18: 975-980. (Pubitemid 38620238)
5. Pham JW, Pellino JL, Lee YS et al. A Dicer-2-dependent 80s complex cleaves targeted mRNAs during RNAi in Drosophila. Cell 2004; 1171: 83-94.
6. Carmell MA, Xuan Z, Zhang MQ, Hannon GJ. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 2002; 16: 2733-2742. (Pubitemid 35253139)
7. Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006; 442: 199-202. (Pubitemid 44086566)
8. Batista PJ, Ruby JG, Claycomb JM et al. PRG-1 and 21U-RNAs interact to form the piRNA complex required for fertility in C. elegans. Mol Cell 2008; 31: 67-78.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
11. Lee RC, Feinbaum RL, Ambras V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854. (Pubitemid 24014542)
12. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75: 855-862. (Pubitemid 24014543)
13. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-21529 (Pubitemid 35403967)
14. Liu CG, Calin GA, Meloon B et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004; 101: 9740-97444. (Pubitemid 38869306)
15. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838. (Pubitemid 40839735)
16. Schmittgen TD, Jiang J, Liu Q, Yang L. A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res 2004; 32: e43.
17. Provenzano M, Mocellin S. Complementary techniques: validation of gene expression data by quantitative real time PCR. Adv Exp Med Biol 2007; 593: 66-73.
18. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006; 25: 6202-6210. (Pubitemid 44527851)
19. Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-11760. (Pubitemid 39095368)
20. Bottoni A, Piccin D, Tagliati F et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol 2005; 204: 280-285. (Pubitemid 40776831)
21. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-8707. (Pubitemid 47437445)
22. Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 2007; 6: 1455-14599.
23. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-17801. (Pubitemid 41549891)
24. Hu Z, Chen J, Tian T et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008; 118: 2600-2608. (Pubitemid 351949787)
25. O'Donnell KA, Wentzel EA, Zeller KI et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-1483
26. Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102: 3627-3632. (Pubitemid 40354662)
27. Visone R, Russo L, Pallante P et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007; 14: 791-798. (Pubitemid 350074067)
28. Fornari F, Gramantieri L, Ferracin M et al. MiR-221 controls CDKN1 C/p57 and CDKN1 B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-5661.
29. Petrocca F, Visone R, Onelli MR et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008; 13: 272-286. (Pubitemid 351318375)
30. Gramantieri L, Ferracin M, Fornari F et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099. (Pubitemid 47037488)
31. Liu Q, Fu H, Sun F et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 2008; 36: 5391-5404.
32. Zhu S, Wu H, Wu F et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18: 350-359. (Pubitemid 351333899)
33. Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545.
34. Roldo C, Missiaglia E, Hagan JP et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-4684. (Pubitemid 46630931)
35. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
36. Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462-4699.
37. Tsuda N, Ishiyama S, Li Y et al. Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clin Cancer Res 2006; 12: 6557-6564. (Pubitemid 44799731)
38. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002; 9: 1327-1333. (Pubitemid 34722311)
39. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-184.
40. Krützfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with "antagomirs". Nature 2005; 438: 685-689.
41. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-726.
42. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003; 17: 438-442.
43. Li W, Cha L. Predicting siRNA efficiency. Cell Mol Life Sci 2007; 64: 1785-1792.
44. Tafer H, Ameres SL, Obernosterer G et al. The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol 2008; 26: 578-583. (Pubitemid 351668044)
45. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007. (Pubitemid 41114035)
46. Soutschek J, Akinc A, Bramlage B et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178. (Pubitemid 39545841)
47. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A 2003; 100: 1844-1848. (Pubitemid 36254536)
48. Tiscornia G, Tergaonkar V, Galimi F, Verma IM. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci USA 2004; 101: 7347-7351. (Pubitemid 38638035)
49. Dave RS. RNAi and tumor angiogenesis: bridging the gap towards anti-cancer therapy? Leuk Res 2007; 31: 421-422.
50. Balasubramanian SP, Cox A, Cross SS et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 2007; 121: 1009-1016.
51. Schneider BP, Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007; 4: 181-189.
52. Chen X, Lin J, Kanekura T et al. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 2006; 66: 11323-11330. (Pubitemid 46009963)
53. Shen HL, Xu W, Wu ZY et al. Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF) 165 expression in human leukemia cells. Leuk Res 2007; 31: 515-521. (Pubitemid 46198943)
54. Kim SE, Choi KY. EGF receptor is involved in WNT3a-mediated proliferation and motility of NIH3T3 cells via ERK pathway activation. Cell Signal 2007; 19: 1554-1564.
55. Niu J, Xu Z, Li XN, Han Z. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitiza- tion of a human liver cancer cell line with mutant P53. Cell Biol Int 2007; 31: 156-164. (Pubitemid 46187102)
56. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004; 431: 211-217. (Pubitemid 39243476)
57. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68-76.
58. Baker BE, Kestler DP, Ichiki AT. Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression. J Biomed Sci 2006; 13: 499-507.
59. Grimm D, Streetz KL, Jopling CL et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541. (Pubitemid 44050158)